CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

oxygen therapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1563 high-titer anti-Sars-CoV-2 plasma Wiki 0.71
drug1564 hormones Wiki 0.71
drug1594 mesenchymal stem cells Wiki 0.71
drug952 Oseltamivir Wiki 0.32

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D017563 Lung Diseases, Interstitial NIH 0.29
D011014 Pneumonia NIH 0.10

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0006515 Interstitial pneumonitis HPO 0.32
HP:0002090 Pneumonia HPO 0.11

There are 2 clinical trials

Clinical Trials

1 Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19

Currently there are no proven treatment option for COVID-19. Human convalescent plasma is an option for COVID-19 treatment and could be available from people who have recovered and can donate plasma.

NCT04333251 Pneumonia, Interstitial Biological: high-titer anti-Sars-CoV-2 plasma Other: oxygen therapy
MeSH:Pneumonia Lung Diseases, Interstitial
HPO:Interstitial pneumonitis Interstitial pulmonary abnormality Pneumonia

Primary Outcomes

Description: reduction in oxygen and ventilation support

Measure: reduction in oxygen and ventilation support

Time: through study completion, an average of 4 weeks

2 Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019

The outbreak of coronavirus disease 2019 (COVID-19) at the end of 2019 has seen numerous patients experiencing severe acute lung injury (ALI), which developed into severe respiratory distress syndrome (ARDS). The mortality was as high as 20% -40%. Due to the lack of effective antiviral treatments, supporting treatment is the predominant therapy for COVID-19 pneumonia. Its cure is essentially dependent on the patient's immunity. While the immune system eliminates the virus, numerous inflammatory cytokines are produced and a cytokine storm occurs in severe cases. Mesenchymal stem cells (MSCs) play an important role in injury repair and immune regulation, showing advantageous prospects in the treatment of COVID-19 pneumonia. MSCs prevent cytokine storms by retarding the TNF-α pathway, alleviate sepsis by modulating macrophages, neutrophils, NK cells, DC cells, T lymphocytes and B lymphocytes. After infused, MSCs aggregate in the lungs, improve the lung microenvironment, protect alveolar epithelia, and improve pulmonary fibrosis and pulmonary function.

NCT04371601 COVID-19 Pneumonia Drug: Oseltamivir Drug: hormones Device: oxygen therapy Procedure: mesenchymal stem cells

Primary Outcomes

Description: Improvement of pulmonary function

Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test

Time: 12 months

Secondary Outcomes

Description: Cytokines level

Measure: Detection of TNF-α levels, IL-10 levels

Time: 1,3,6,12months

Description: Immunological status

Measure: Detection of immune cells that secret cytokines, including CXCR3+, CD4+, CD8+, NK+ cells, and regulatory T cells (CD4 + CD25 + FOXP3 + Treg cells).

Time: 1,3,6,12months

Description: Improvement of pulmonary function

Measure: Changes of oxygenation index (PaO2/FiO2) ,blood gas test

Time: 1,3,6months

Description: Infection biomarkers

Measure: Changes of c-reactive protein and calcitonin

Time: 1,3,6,12months

Related HPO nodes (Using clinical trials)